%0 Journal Article
%T Multimodal Treatment Superiority in Osteoarthritis: Insights from a Dagestani Cohort Study (2022-2024)
%A Valeriia Valerievna Volobueva
%A Aida Sulitdinovna Ayubova
%A Karina Ernestovna Urudzheva
%A Kamilla Ernestovna Urudzheva
%A Guzel Islamovna Zeynalova
%A Khabib Sagdulaevich Dzhairulaev
%A Islam Omargadzhievich Ibragimov
%A Selima Badrudievna Idalova
%J Journal of Biochemical Technology
%@ 0974-2328
%D 2025
%V 16
%N 2
%R 10.51847/cV7BDzw1om
%P 49-56
%X This prospective observational study evaluated the efficacy and safety of different treatment modalities in 240 osteoarthritis (OA) patients (mean age 58.7±9.2 years; 68.3% female) at a diagnostic center in the Republic of Dagestan from 2022 to 2024. Patients were stratified into four treatment groups: NSAIDs (n=72), chondroprotectors (n=60), hyaluronic acid (HA) injections (n=54), and combination therapy (n=54). Primary outcomes included changes in pain intensity (VAS) and functional status (WOMAC) at 12 months. Combination therapy demonstrated superior clinical outcomes, with 41.7% of patients achieving ≥50% pain reduction compared to 22.2% in the NSAID group (p=0.008). Mean WOMAC improvement was significantly greater with combination therapy (-35.2±10.1%) versus monotherapies (p
%U https://jbiochemtech.com/article/multimodal-treatment-superiority-in-osteoarthritis-insights-from-a-dagestani-cohort-study-2022-202-jpqlh4edq9shxik